Gelteq Ltd
NASDAQ:GELS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Gelteq Ltd
Common Stock
Gelteq Ltd
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Gelteq Ltd
NASDAQ:GELS
|
Common Stock
AU$33.9m
|
CAGR 3-Years
10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Common Stock
AU$81.7m
|
CAGR 3-Years
23%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Common Stock
AU$1.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Common Stock
AU$134.9m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
2%
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Common Stock
AU$255.9m
|
CAGR 3-Years
25%
|
CAGR 5-Years
61%
|
CAGR 10-Years
N/A
|
|
|
Nyrada Inc
ASX:NYR
|
Common Stock
AU$38.2m
|
CAGR 3-Years
15%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
Gelteq Ltd
Glance View
Gelteq Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Melbourne, Victoria. The company went IPO on 2024-10-29. Gelteq Limited is an Australia-based clinical and science-based company. The firm is focused on developing and commercializing white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products. The firm offers a complete end-to-end service for the development of new products and the conversion of existing products and formulations into gels. Its product suite consists of multiple products that sit within five core verticals - for pets, sports, pharmaceuticals (pharma), over-the-counter (OTC) and nutraceuticals. The Company’s delivery system provides pharma and nutraceutical enhancements throughout every stage of ingestion in both animals and humans, addressing the complete experience from the point of ingestion to final absorption. The firm also offers a highly versatile portfolio of pre-tested and market-ready proprietary formulations that can be white-labelled.
See Also
What is Gelteq Ltd's Common Stock?
Common Stock
33.9m
AUD
Based on the financial report for Jun 30, 2025, Gelteq Ltd's Common Stock amounts to 33.9m AUD.
What is Gelteq Ltd's Common Stock growth rate?
Common Stock CAGR 3Y
10%
Over the last year, the Common Stock growth was 28%. The average annual Common Stock growth rates for Gelteq Ltd have been 10% over the past three years .
